

Trust Board in Public

Thursday, 8th September 2022

Report Title:	Research & Innovation Annual Report 2021-22
Executive/NED Lead:	Dr Shane Gordon, Director of Strategy, Research & Innovation
Report author(s):	Dr Shane Gordon
Previously considered by:	People and Organisational Development Committee 28 July 2022 Research Governance Group

Approval
 Discussion
 Information
 Assurance

BAF Risks: (4) Transformation, (7) COVID recovery

Executive summary		
<p>The annual report for Research and Innovation is attached.</p> <p>The Trust continues to expand a vigorous programme of work which involves a wide range of departments.</p> <p>Research activity has grown over the last year, particularly in commercial research, in-house research and collaborative academic research with our local university partners.</p> <p>Innovation activity has included significant developments in training, education, Artificial Intelligence (AI), pathology, robotic surgery and support to innovators.</p> <p>A slide presentation has been prepared to provide the highlights of the report. Research and innovation will also be included on the agenda for the Annual Members Meeting in November.</p>		
Action requested of the Board		
The Board is recommended to receive the annual report		
Link to Strategic Objectives (SO)		Please tick
SO1	Keep people in control of their health	<input checked="" type="checkbox"/>
SO2	Lead the integration of care	<input checked="" type="checkbox"/>
SO3	Develop our centres of excellence	<input checked="" type="checkbox"/>
SO4	Support and develop our staff	<input checked="" type="checkbox"/>
SO4	Drive technology enabled care	<input checked="" type="checkbox"/>
Risk Implications for the Trust (including any clinical and financial consequences)		Organisations which are active in clinical research are demonstrated to achieve superior outcomes for patients. Clinical research forms part of regulatory assessment for the Trust.
Trust Risk Appetite		Innovation: The Board has an open view of innovation that supports quality, patient safety and operation effectiveness. This means that it is eager to pursue innovation and challenge current working practices, and views new technologies as a key enabler of operational delivery. However, decision making authority will be carefully managed to ensure that prioritization and focus on the identification and delivery of innovations with transformative potential and will only be devolved on the basis of earned autonomy.

Legal and regulatory implications (including links to CQC outcomes, Monitor, inspections, audits, etc)	Active participation in research is part of the Care Quality Commission well led domain. Clinical trials are subject to regulation by MHRA (Medicines and Healthcare products Regulation Agency).
Financial Implications	
Equality and Diversity	Equality impact assessment is undertaken for each scheme separately. There are no plans in this programme that will impinge on the rights of staff of patients / carers under current legislation.